In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Growth

Set Alert for Growth

Managing Pharma's Competing Challenges In The New Health Economy

The shifts roiling the health care industry are creating an entirely new commercial landscape. PwC says that the way pharma companies opt to address three pivotal challenges – patient engagement, analytics and value – will affect not only their future, but the future direction of patient care, provider decisions and payment mechanisms.

Business Strategies Pricing Strategies Growth
Advertisement

Latest From Growth

Regression To The Meanest: How Markets Value Pharma Stocks

Financial markets – the people and institutions that lend companies money and estimate their worth – see pharma companies as revenue-generating, profit-sharing black boxes. Growth earns companies a break from this simplistic view, but sooner or later market valuations of pharmas seem to regress to a mean based on revenue multiples. That mean is getting meaner.

Business Strategies Financing

Cardio-Neuro Innovator LivaNova Prepares For Challenges Ahead

LivaNova was formed from the merger of cardiovascular disease therapy company Sorin Group and neuromodulation innovator Cyberonics. The role and place in the industry of this new mega group might not be obvious to all, but incoming CEO Damien McDonald already has a vision of creating a disciplined company that leverages synergies and gets closer to the customer base.

Business Strategies Growth

Integra Thinks High Margin, Differentiated Portfolio Can Deliver A Transformative 2017

Integra LifeSciences surged to industry-leading 12% sales growth in 2016, and that's before it prepares to consolidate two of the biggest acquisitions in its history. What is the strategy behind the success of the specialty surgery, orthopedics and tissue tech company that is looking at another double-digit sales uplift in 2017?

Orthopedics Wound Healing & Tissue Repair

Personalized Medicine: What's Your Strategy?

Free content: Personalized medicine is upending the business of health care. In March, In Vivo will focus on exploring this new landscape. There is no single "right" route for companies to follow, but pharma, payers and other stakeholders need to find a path because the forces driving personalized medicine are global, and unstoppable.

BioPharmaceutical Growth

Cystic Fibrosis: Successes, Opportunities And Challenges

What is next for the treatment of cystic fibrosis, a rare disease market that has boomed in recent years on the back of new drug approvals with hefty price tags? Pipelines are full, but securing reimbursement is a challenge.

Growth Research and Development Strategies

Category Focus Rewards Biopharma Shareholders

For decades, biopharma companies have relentlessly pursued growth, counting on pure scale and M&A cost synergies to create value. This strategy is reaching its limits and becoming counterproductive, according to Bain & Co. analysis. Megamergers that don’t produce category leaders also don’t create portfolios that are likely to deliver attractive shareholder returns over time.

BioPharmaceutical Business Strategies
See All
UsernamePublicRestriction

Register